Eliza Slawther
Senior Writer
Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
EU Borderline Product Court Ruling Puts Tricky ‘Negative Burden Of Proof’ On Manufacturers
When is a borderline drug/device product a medical device? Only when the manufacturer can prove that is definitely not a medicine, according to a new EU Court of Justice ruling. Expert medtech regulatory lawyer Erik Vollebregt outlines his main criticisms of this judgment.
EU Regulatory Round-Up, January 2023: Cautious Optimism As New MDR Proposal Unveiled
All eyes were on the European Commission in January as it edged closer to adopting new legislation that will see the Medical Device Regulation transition deadlines extended.
EU Digital Tech Trade Body Weighs In On Medical Device ‘Over-Regulation’ Risk
While the European Health Data Space and its objectives should be a positive regulatory development for the EU health sector, DIGITALEUROPE stresses that the risk of counterproductive conflicts with other proposed laws around AI and data must be addressed.
EU Borderline Product Court Ruling Puts Tricky “Negative Burden Of Proof” On Manufacturers
When is a borderline drug/device product a medical device? Only when the manufacturer can prove that is definitely not a medicine, according to a new EU Court Of Justice ruling. Expert medtech regulatory lawyer Erik Vollebregt outlines his main criticisms of this judgment.
EMA Expert Advice Pilot Could Be ‘Vital Source Of Guidance’ For SMEs
Ten medical device manufacturers will receive scientific advice from expert panels on their product clinical development strategies under a new European Medicines Agency pilot scheme. But who will it ultimately benefit and what does the scheme entail?
EU Taps Power Of AI To Beat Cancer In New Imaging Initiative
The European Commission’s newly-launched Cancer Imaging Initiative will see sophisticated digital technologies based on artificial intelligence used to speed up medical innovations as part of its wider Beating Cancer Plan.